Amyloid "accumulators": The next generation of candidates for amyloid-targeted clinical trials?

Corey T McMillan¹, Gael Chételat²

• ¹From the Department of Neurology (C.T.M.), Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia; and Inserm UMR-S U1237 (G.C.), Université de Caen-Normandie, GIP Cyceron, Caen, France. mcmillac@upenn.edu.+1